| CARLAT PUBLISHING

Learning Objectives, Inflammation and Depression, TCPR, February 2020

After reading these articles, you should be able to… Read More

Highlights From This Issue

Quick hints on what you’ll find in this issue. Read More

An Answer for Psychotic Depression

Research tells us how to start meds, but rarely when to stop them. This study brings some needed answers on discontinuing antipsychotics after recovery from psychotic depression. Read More

Nuedexta is indicated for pseudobulbar affect, but when the manufacturer attempted to expand its use into agitation in dementia they ran into some heavy legal penalties. Here we take a closer look at the published and unpublished trials to see what ─ if anything ─ is salvageable. We’ll also show you how to prescribe this high-cost drug as a generic equivalent. Read More

Inflammatory Biomarkers in Depression

Andrew Miller, Vice Chair of Psychiatry Research at Emory University, translates two decades research on inflammation and depression into practical terms, including a low-cost biomarker that may guide antidepressant selection. Read More

How to Use Pramipexole

Pramipexole is a selective agonist at the dopamine D3 receptor, which is thought to regulate hedonic drive. It is FDA approved in Parkinson’s disease and restless legs syndrome, and has five randomized controlled trials in depression. Read More

Polypharmacy in Schizophrenia

Polypharmacy is often practiced in schizophrenia, but you have to look hard to find any evidence that it helps. These two large-scale studies lend some empiric support to the practice, but also give us insights into how it could go wrong. Read More

CME Post-Test - Inflammation and Depression, TCPR, February 2020

The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit. Read More